About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

EiRx Therapeutics PLC
13 August 2007


For Immediate Release 13 August 2007



EIRX THERAPEUTICS PLC

('EiRx' or 'the Company')

362,000 grant supports cancer drug development programme

New chemistry capability advances EiRx from drug discovery to development, will
drive products towards clinical candidacy


Cork, Ireland - EiRx Therapeutics plc (AIM: ERX), the drug discovery company
developing targeted therapies for cancer, is pleased to announce that Enterprise
Ireland has agreed to fund the development of new cancer medicines through a
collaboration with Professor Anita Maguire, Chair of Pharmaceutical Chemistry at
University College Cork ('UCC'), Ireland. The collaboration will establish a
medicinal chemistry team in Cork, under the supervision of Prof Maguire, to
optimise compounds emerging from the Company's EnPADTM drug discovery platform
and advance them towards clinical trials. The tie-up with Professor Maguire, who
is Director of UCC's prestigious Analytical & Biological Chemistry Research
Facility ('ABCRF'), has attracted funding through Enterprise Ireland's
Innovation Partnership scheme. The grant awards a total of 362,600 over two
years for personnel, materials and overhead costs, and will be reinforced by
EiRx with a further 139,000 in cash and dedicated personnel costs.


As a result of the collaboration, EiRx gains access to medicinal chemistry
skills and facilities via employment of two fully-funded postdoctoral chemists
within Professor Maguire's research group at the ABCRF. Professor Maguire will
lead in the scientific management and leadership of the research programme, and
EiRx will contribute a dedicated cancer biologist and management input. The
collaboration will work on optimisation of tumour-selective pro-apoptotic
molecules identified by EiRx's proprietary EnPADTM platform. Any optimised drug
candidates resulting will then be advanced to formal preclinical and clinical
evaluation.


The collaboration is expected to commence within weeks, and will focus on the
most promising examples from EiRx's panel of molecules with proven selective
biological activity against colon and breast cancer cell lines. The partners
will work over a two year period on the optimisation of multiple compound
series, from which preclinical leads will be selected in due course. Novel
intellectual property generated by the collaboration will be jointly held by the
partners. EiRx will assume responsibility for product development beyond the
lead optimisation stage, and will pay success-based development milestones of up
to 3M per new therapeutic candidate, plus royalties on sales, in return for
exclusive, worldwide rights over UCC's stake in jointly held IP.


Dr Colin Telfer, Chief Executive Officer of EiRx, stated: 'Professor Anita
Maguire is a scientist of the highest standing whose scientific input will help
EiRx deliver next-generation cancer therapeutics to the clinic. We have
identified a lack of medicinal chemistry and lead optimisation skills as a
limiting factor on our ability to advance EiRx's drug development programmes,
and it is gratifying to have secured these skills though enlistment of Professor
Maguire's internationally recognised capabilities. Furthermore, we are delighted
that our efforts have secured the financial backing of Enterprise Ireland. We
see this initiative as the foundation stone of our own dedicated chemistry
capability, which we plan to develop from our operational base in Cork, and we
now look forward to optimising our drug candidates in preparation for clinical
evaluation.'

not much change in the sp !Still a long way to go till we see the BIG 1p

Where is PH these days?; gone very quiet! The latest from Eirx is 'not so good/not so bad'


EiRx Therapeutics PLC
08 November 2007
Notice of general meeting
Business update


The Company is today posting to shareholders a notice convening a general
meeting to be held at noon on 5th December 2007 at the offices of Shepherd and
Wedderburn LLP, Condor House, 10 St Paul's Churchyard, London EC4M 8AL, at which
shareholders will be asked to approve a reorganisation of the Company's share
capital including the division of each EiRx Therapeutics plc ordinary share of
0.2p each into one ordinary share of 0.001p and one deferred share of 0.199p and
the division of each unissued EiRx ordinary share of 0.2p into 200 ordinary
shares of 0.001p. Shareholders are also being asked to give the directors
additional authorities to issue shares for cash.

The Company currently generates limited revenue and needs to raise funds to
support its operations. It has been able to postpone a fundraising for longer
than anticipated through careful control of expenditure and greater than
anticipated grant income. The Company is also pleased to announce that it has
secured a bank overdraft facility of 200,000 that has been guaranteed by Peter
Hoskins. As part of these arrangements, a charge has been granted over the EiRx
group's assets. Even with the benefit of that facility, the Company will need
to raise additional funds by the end of January 2008 in order to continue
trading.

The resolutions are being proposed to enable EiRx to raise funds through a
placing of shares, for which it has received indications of interest, which it
is unable to undertake at present because the current market price of the
Company's shares is below their nominal value. Should the placing be
successful, the funds raised will provide working capital to enable the Company
to continue its drug development programme and its business development
activities. In this regard, the Company is pleased to be announcing today an
update of its drug discovery efforts, including details of new patents filed to
protect novel drug candidates discovered using its EnPAD(TM) cellular screening
technology platform.

The general meeting will be preceded by a technical briefing which will commence
at 10:30 a.m.

So, that was the maybe 'not so good'. Perhaps 'not so bad' is:-

Notable achievements in 2006/7 include:

Development of the EnPAD(TM) drug screening technology to enable
identification of compounds that specifically target cell survival
pathways.

Filing of patent applications on first series of potential anti-cancer
compounds identified using EnPAD(TM), which target the b-catenin signalling
pathway to selectively kill colorectal and breast cancer cells in vitro.

Collaborative research agreement with international diagnostics major
bioMerieux SA.

A total of 2.2M raised for research and development by issue of new
shares, comprising three placements of 1.2M, 0.5M and 0.5M on 31st March
2006, 21st September 2006 and 4th January 2007 respectively.

An R&D alliance with the Analytical & Biological Chemistry Research
Facility ('ABCRF') at University College Cork, to apply the medicinal
chemistry expertise of Professor Anita Maguire and her team to the
optimisation of potential new cancer drugs from EiRx's EnPAD(TM) discovery
platform.

A 362,000 grant from Enterprise Ireland's Innovation Partnership
programme, to support the collaborative drug development alliance with
Professor Maguire and the ABCRF.

For further information please see our website at
http://www.eirx.com

EiRx Therapeutics PLC said it has filed two new patent applications to protect novel drug candidates discovered using its EnPAD platform.

'EiRx's EnPAD technology has again uncovered novel and potently active small molecule drug candidates which are specifically targeting signal pathways know to become dysregulated in cancer cells,' Finbarr Murphy, managing director of EiRx's Cork research laboratory, said.

Maybe there is life in the old dog yet!

Out at the moment last week, I may get back in after the fund raising next Jan.

I'm still holding 2m Driver, decided a while ago to hang on 'til the end, or new beginning, whichever it may be!

Perhaps the end of the beginning or more likely the beginning of the end!

Lol!

Where is spud nowadays?

Still Ramping on ADVFN !!

http://www.biotechnologyireland.com/pooled/articles/BF_EVENTART/view.asp?Q=BF_EVENTART_293930

EiRx Therapeutics PLC
05 December 2007



EIRX THERAPEUTICS PLC ('the Company')

Result of general meeting

At the general meeting of the Company held earlier today, all resolutions were
passed.

Application has been made for the re-admission of the Company's ordinary shares
to trading on AIM as Ordinary Shares of 0.001p with trading under the new
designation expected to commence on 6 December 2007.

With effect from re-admission the Company will have 2,975,743,260 Ordinary
Shares of 0.0001p each in issue.

EiRx Therapeutics PLC
05 February 2008


EIRX THERAPEUTICS PLC ('EiRx' or 'the Company')

Update on funding


On 8 November 2007, the Company stated that it would need to raise additional
funds by the end of January 2008. The Company has managed its resources such
that it must now undertake a fundraising by 15 February 2008 if it is to
continue trading beyond that date although the Company is currently dependent on
the support of Billam AG and Peter Hoskins that may be withdrawn at any time.

Despite the current difficult market conditions, the Company is currently
attempting to complete a fundraising package with the support of a shareholder,
Billam AG which is intended to give the Company sufficient working capital to
last until the end of 2008. Should the Company fail to complete a fundraising by
15 February, it will be obliged to cease operations. The Company will make a
further announcement as soon as possible, and in any event no later than 15
February.


For further information, please contact:

POT HEAD !!!

5m sold at .0002 not good.

NEWS ALERT
NICK LEESON SEEN IN MY BANK TRYING TO SELL MY 5M ERIX SHARES, BUT THEY RECOGNISED HIM !!! OH NO SORRY, MY MISTAKE, IT WAS THE SHARES NOT HIM THAT WAS THE PROBLEM

Driver, Dire, you obviously do not think they will get funding ?
I am still holding in one hand and a large brandy in the other one

Whatever happens, there is a maximum of 10 days trading this share before it goes tits up or survives to torment us until the end of the year; I think I prefer the latter!

me too !

MEEE TOOOO I,AM GETTING HALF PISSED NOW "HIC HIC" SO I DO NOT CARE MUCH
WEALTH WARNING SHARE DEALING CAN SERIOUSLY DAMAGE YOUR WEALTH

GOING.... going..... g....

HALIFAX, HOW DO YOU KNOW I FELL OF THE BAR STALL, ARE YOU IN THIS PUB ?

I'm lying here hoping you won't fall on me!